NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Martin Marietta Buys Lhoist North America for $13.5 Billion in Cash and Stock

The acquisition adds over 2 billion tons of limestone reserves and creates $85M in annual synergies.

Martin Marietta Buys Lhoist North America for $13.5 Billion in Cash and Stock
Credit: Bloomberg
Already have an account? Sign in.
Featured/ 06/29/2026 · 9:31 AM
MLM
/ Read more

Feed↓

BofA Downgrades Biohaven to Underperform, Cuts Price Target to $11 on Kv7 Risks
Featured/ 06/29/2026 · 10:31 AM

BofA Downgrades Biohaven to Underperform, Cuts Price Target to $11 on Kv7 Risks

Analyst highlights competition risk in Kv7 epilepsy program and cuts peak sales forecast.

/ Subscriber only
Evommune’s EVO756 Fails Phase 2b Trial in Chronic Spontaneous Urticaria, Development Discontinued
Featured/ 06/29/2026 · 10:04 AM

Evommune’s EVO756 Fails Phase 2b Trial in Chronic Spontaneous Urticaria, Development Discontinued

Evommune reported EVO756 failed to meet its primary endpoint in the Phase 2b CSU trial. The company is discontinuing development in urticaria but advancing the drug in atopic dermatitis with data expected in Q3 2026.

/ Subscriber only
Nomlabofusp Shows 100% Frataxin Response in Friedreich’s Ataxia — But Anaphylaxis Risk Weighs on Shares
Featured/ 06/29/2026 · 9:03 AM

Nomlabofusp Shows 100% Frataxin Response in Friedreich’s Ataxia — But Anaphylaxis Risk Weighs on Shares

Positive long-term data for Larimar’s nomlabofusp in Friedreich’s ataxia: 100% frataxin response and walking recovery signals. FDA accelerated pathway opens, but safety issues weigh on stock.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe